The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | PD-1 blockade as salvage following anti-BCMA CAR-T in R/R myeloma
PD-1 checkpoint inhibitor combination regimens are being investigated as a salvage therapy for relapsed/refractory multiple myeloma patients who progress after anti-BCMA CAR T-cell therapy, as discussed here by Adam Cohen, MD, of the University of Pennsylvania, Philadelphia, PA. Dr Cohen highlights the results; that this combination can induce re-expansion of the CAR T-cells, although this effect was transient and infrequent. This indicates that certain patients may respond to this strategy or other immune-modulating approaches. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
